Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057523 · ClinicalTrials.gov registry record · Phase 4
Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
A Phase 4 study, sponsored by University of Illinois at Chicago.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT02057523 is a Phase 4 study that was terminated before completion, run by University of Illinois at Chicago. The registered enrollment target is 2 participants.
The verdict
NCT02057523, a Phase 4 study, was terminated before completion, sponsored by University of Illinois at Chicago.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the benefit of ACTH (Acthar) in reducing proteinuria associated with transplant glomerulopathy in non-diabetic kidney transplant recipients.
Interventions
- DRUG Acthar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02057523
The ClinicalTrials.gov registry entry for NCT02057523 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acthar is the first listed.
NCT02057523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02057523 about?
NCT02057523 is a clinical study titled "Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients". The goal of this study is to evaluate the benefit of ACTH (Acthar) in reducing proteinuria associated with transplant glomerulopathy in non-diabetic kidney transplant recipients.
What is the current status of trial NCT02057523?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2014-09. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02057523?
The interventions under investigation include: Acthar (DRUG).
Who is sponsoring clinical trial NCT02057523?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.